Does the media prefer KNSA or ALVO?

In the previous week, Kiniksa Pharmaceuticals International and Kiniksa Pharmaceuticals International both had 4 articles in the media. Kiniksa Pharmaceuticals International's average media sentiment score of 1.08 beat Alvotech's score of 0.97 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMRX or ALVO?

In the previous week, Alvotech had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 4 mentions for Alvotech and 3 mentions for Amneal Pharmaceuticals. Alvotech's average media sentiment score of 0.97 beat Amneal Pharmaceuticals' score of 0.78 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALVO or TWST?

In the previous week, Alvotech had 1 more articles in the media than Twist Bioscience. MarketBeat recorded 4 mentions for Alvotech and 3 mentions for Twist Bioscience. Alvotech's average media sentiment score of 0.97 beat Twist Bioscience's score of 0.88 indicating that Alvotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRNX or ALVO?

In the previous week, Alvotech had 2 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 4 mentions for Alvotech and 2 mentions for Crinetics Pharmaceuticals. Alvotech's average media sentiment score of 0.97 beat Crinetics Pharmaceuticals' score of 0.93 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alvotech (ALVO) Competitors

$3.22 -0.14 (-4.17%)

Closing price 06/1/2026 04:00 PM Eastern

Extended Trading

$3.25 +0.03 (+0.93%)

As of 06/1/2026 06:52 PM Eastern

Compare

ALVO vs. KNSA, AMRX, TWST, CRNX, and CPRX

Should you buy Alvotech stock or one of its competitors? MarketBeat compares Alvotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alvotech include Kiniksa Pharmaceuticals International (KNSA), Amneal Pharmaceuticals (AMRX), Twist Bioscience (TWST), Crinetics Pharmaceuticals (CRNX), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry.

How does Alvotech compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

In the previous week, Kiniksa Pharmaceuticals International and Kiniksa Pharmaceuticals International both had 4 articles in the media. Kiniksa Pharmaceuticals International's average media sentiment score of 1.08 beat Alvotech's score of 0.97 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	5.50	$59.01M	$0.90	53.81
Alvotech	$588.90M	1.65	$27.92M	-$0.25	N/A

Kiniksa Pharmaceuticals International has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

Kiniksa Pharmaceuticals International currently has a consensus price target of $60.86, indicating a potential upside of 25.66%. Alvotech has a consensus price target of $7.60, indicating a potential upside of 136.02%. Given Alvotech's higher possible upside, analysts plainly believe Alvotech is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Alvotech's net margin of -14.36%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Alvotech	-14.36%	-11.92%	-7.58%

Summary

Kiniksa Pharmaceuticals International beats Alvotech on 13 of the 15 factors compared between the two stocks.

How does Alvotech compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Amneal Pharmaceuticals has a net margin of 4.01% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Alvotech	-14.36%	-11.92%	-7.58%

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Amneal Pharmaceuticals has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.05B	1.35	$72.06M	$0.38	33.95
Alvotech	$588.90M	1.65	$27.92M	-$0.25	N/A

In the previous week, Alvotech had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 4 mentions for Alvotech and 3 mentions for Amneal Pharmaceuticals. Alvotech's average media sentiment score of 0.97 beat Amneal Pharmaceuticals' score of 0.78 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals currently has a consensus target price of $15.17, indicating a potential upside of 17.57%. Alvotech has a consensus target price of $7.60, indicating a potential upside of 136.02%. Given Alvotech's higher probable upside, analysts plainly believe Alvotech is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Amneal Pharmaceuticals has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

Summary

Amneal Pharmaceuticals beats Alvotech on 11 of the 16 factors compared between the two stocks.

How does Alvotech compare to Twist Bioscience?

Alvotech (NASDAQ:ALVO) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Alvotech has a net margin of -14.36% compared to Twist Bioscience's net margin of -19.85%. Alvotech's return on equity of -11.92% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.58%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Alvotech has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	1.65	$27.92M	-$0.25	N/A
Twist Bioscience	$376.57M	11.22	-$77.67M	-$1.33	N/A

In the previous week, Alvotech had 1 more articles in the media than Twist Bioscience. MarketBeat recorded 4 mentions for Alvotech and 3 mentions for Twist Bioscience. Alvotech's average media sentiment score of 0.97 beat Twist Bioscience's score of 0.88 indicating that Alvotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alvotech has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market.

Alvotech currently has a consensus price target of $7.60, suggesting a potential upside of 136.02%. Twist Bioscience has a consensus price target of $58.00, suggesting a potential downside of 14.53%. Given Alvotech's higher possible upside, research analysts clearly believe Alvotech is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Alvotech beats Twist Bioscience on 10 of the 14 factors compared between the two stocks.

How does Alvotech compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Alvotech has higher revenue and earnings than Crinetics Pharmaceuticals. Alvotech is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	472.70	-$465.32M	-$5.13	N/A
Alvotech	$588.90M	1.65	$27.92M	-$0.25	N/A

Alvotech has a net margin of -14.36% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Alvotech's return on equity of -11.92% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Alvotech	-14.36%	-11.92%	-7.58%

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Alvotech had 2 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 4 mentions for Alvotech and 2 mentions for Crinetics Pharmaceuticals. Alvotech's average media sentiment score of 0.97 beat Crinetics Pharmaceuticals' score of 0.93 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Crinetics Pharmaceuticals presently has a consensus price target of $76.13, suggesting a potential upside of 120.52%. Alvotech has a consensus price target of $7.60, suggesting a potential upside of 136.02%. Given Alvotech's higher possible upside, analysts clearly believe Alvotech is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Crinetics Pharmaceuticals has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

Summary

Alvotech beats Crinetics Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Alvotech compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Alvotech's net margin of -14.36%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Alvotech	-14.36%	-11.92%	-7.58%

In the previous week, Alvotech had 3 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 4 mentions for Alvotech and 1 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.30 beat Alvotech's score of 0.97 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Catalyst Pharmaceuticals	Positive
Alvotech	Positive

Catalyst Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

Catalyst Pharmaceuticals has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.50	$214.33M	$1.74	17.97
Alvotech	$588.90M	1.65	$27.92M	-$0.25	N/A

Catalyst Pharmaceuticals currently has a consensus target price of $32.00, indicating a potential upside of 2.33%. Alvotech has a consensus target price of $7.60, indicating a potential upside of 136.02%. Given Alvotech's higher probable upside, analysts clearly believe Alvotech is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Catalyst Pharmaceuticals beats Alvotech on 14 of the 17 factors compared between the two stocks.

Get Alvotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVO vs. The Competition

Export

Metric	Alvotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.01B	$3.40B	$6.43B	$12.56B
Dividend Yield	N/A	2.28%	2.69%	5.30%
P/E Ratio	-12.88	17.92	21.34	26.63
Price / Sales	1.65	329.55	549.62	111.59
Price / Cash	15.42	54.19	27.44	37.60
Price / Book	-3.43	6.84	9.95	6.88
Net Income	$27.92M	$24.15M	$3.56B	$336.73M
7 Day Performance	-5.85%	1.15%	1.63%	3.07%
1 Month Performance	-6.94%	3.78%	6.25%	7.13%
1 Year Performance	-71.30%	58.49%	34.52%	38.42%

Alvotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVO Alvotech	3.6934 of 5 stars	$3.22 -4.2%	$7.60 +136.0%	-72.2%	$1.01B	$588.90M	N/A	1,460
KNSA Kiniksa Pharmaceuticals International	4.4214 of 5 stars	$53.39 +0.3%	$60.86 +14.0%	+76.6%	$4.11B	$677.56M	59.32	220	Positive News
AMRX Amneal Pharmaceuticals	4.0104 of 5 stars	$12.69 +2.2%	$15.17 +19.5%	+75.0%	$4.05B	$3.02B	33.40	8,500
TWST Twist Bioscience	1.1868 of 5 stars	$64.75 +6.9%	$58.00 -10.4%	+129.9%	$4.03B	$376.57M	N/A	990
CRNX Crinetics Pharmaceuticals	3.4955 of 5 stars	$36.50 -0.8%	$76.13 +108.6%	+12.8%	$3.85B	$7.70M	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVO) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alvotech (ALVO) Competitors

ALVO vs. KNSA, AMRX, TWST, CRNX, and CPRX

How does Alvotech compare to Kiniksa Pharmaceuticals International?

Summary

How does Alvotech compare to Amneal Pharmaceuticals?

Summary

How does Alvotech compare to Twist Bioscience?

Summary

How does Alvotech compare to Crinetics Pharmaceuticals?

Summary

How does Alvotech compare to Catalyst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO vs. The Competition

Alvotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alvotech (ALVO) Competitors

ALVO vs. KNSA, AMRX, TWST, CRNX, and CPRX

How does Alvotech compare to Kiniksa Pharmaceuticals International?

Does the media prefer KNSA or ALVO?

Do institutionals & insiders have more ownership in KNSA or ALVO?

Which has higher earnings & valuation, KNSA or ALVO?

Which has more volatility & risk, KNSA or ALVO?

Do analysts recommend KNSA or ALVO?

Is KNSA or ALVO more profitable?

Summary

How does Alvotech compare to Amneal Pharmaceuticals?

Is AMRX or ALVO more profitable?

Do insiders & institutionals have more ownership in AMRX or ALVO?

Which has better valuation & earnings, AMRX or ALVO?

Does the media prefer AMRX or ALVO?

Do analysts rate AMRX or ALVO?

Which has more risk & volatility, AMRX or ALVO?

Summary

How does Alvotech compare to Twist Bioscience?

Is ALVO or TWST more profitable?

Which has stronger earnings and valuation, ALVO or TWST?

Does the media favor ALVO or TWST?

Which has more risk & volatility, ALVO or TWST?

Do analysts rate ALVO or TWST?

Summary

How does Alvotech compare to Crinetics Pharmaceuticals?

Which has higher earnings and valuation, CRNX or ALVO?

Is CRNX or ALVO more profitable?

Do institutionals & insiders hold more shares of CRNX or ALVO?

Does the media prefer CRNX or ALVO?

Do analysts recommend CRNX or ALVO?

Which has more volatility & risk, CRNX or ALVO?

Summary

How does Alvotech compare to Catalyst Pharmaceuticals?

Do institutionals & insiders believe in CPRX or ALVO?

Is CPRX or ALVO more profitable?

Does the media prefer CPRX or ALVO?

Which has more volatility and risk, CPRX or ALVO?

Which has stronger earnings & valuation, CPRX or ALVO?

Do analysts rate CPRX or ALVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO vs. The Competition

Alvotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools